Abstract
The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise.
| Original language | English |
|---|---|
| Article number | 5 |
| Journal | Biomarker Research |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2 2015 |
Keywords
- Clear cell
- Non-clear cell
- PD-1
- Renal cell carcinoma
- Tyrosine kinase inhibitor
Fingerprint
Dive into the research topics of 'Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver